Update 7 April 2025

Today the Scottish Medicines Consortium (SMC) accepted Elafibranor for use in NHS Scotland.
Read the full press release below.

It has been an incredibly exciting and dynamic 6 months, with huge progress made for those living with PBC, particularly those who do not fully respond to or cannot tolerate Urso (UDCA).

We have both Elafibranor (Iqirvo) and Seladelpar (Livdelzi) approved in the US, albeit on the condition of further studies. We also have both drugs approved in the UK – without the need for further studies – with Elafibranor already being reimbursed by NICE in England. 

This situation will continue to develop as patients in more countries gain access to these important drugs, so do keep revisiting this page for updates as we have them.

Official press releases below:

Elafibranor (Iqirvo)

https://www.gov.uk/government/news/elafibranor-approved-as-first-medicine-to-treat-adults-with-a-rare-liver-disease-known-as-primary-biliary-cholangitis

U.K. MHRA grants marketing authorisation for Ipsen’s Iqirvo® (elafibranor), a first-in-class peroxisome proliferator-activated receptor (PPAR) treatment for primary biliary cholangitis (PBC) – Ipsen UK

NICE recommends Ipsen’s IQIRVO® (elafibranor) – the first medicine approved for NHS use in nearly a decade for primary biliary cholangitis (PBC), a rare liver disease – Ipsen UK

The Scottish Medicines Consortium (SMC) accepts Ipsen’s IQIRVO® (elafibranor) for use in NHS Scotland – the first new medicine in nearly a decade for primary biliary cholangitis (PBC), a rare liver disease – Ipsen UK

Seladelpar (Livdelzi)

https://www.gov.uk/government/news/seladelpar-approved-to-treat-adult-patients-in-the-uk-with-liver-illness